CY1110879T1 - ΧΑΡΑΚΤΗΡΙΣΜΟΣ: ΑΝΑΜΙΚΤΟΙ ORL1/μ-ΑΓΩΝΙΣΤΕΣ ΓΙΑ ΤΗ ΘΕΡΑΠΕΙΑ ΠΟΝΟΥ - Google Patents
ΧΑΡΑΚΤΗΡΙΣΜΟΣ: ΑΝΑΜΙΚΤΟΙ ORL1/μ-ΑΓΩΝΙΣΤΕΣ ΓΙΑ ΤΗ ΘΕΡΑΠΕΙΑ ΠΟΝΟΥInfo
- Publication number
- CY1110879T1 CY1110879T1 CY20101100993T CY101100993T CY1110879T1 CY 1110879 T1 CY1110879 T1 CY 1110879T1 CY 20101100993 T CY20101100993 T CY 20101100993T CY 101100993 T CY101100993 T CY 101100993T CY 1110879 T1 CY1110879 T1 CY 1110879T1
- Authority
- CY
- Cyprus
- Prior art keywords
- orl1
- receptor
- agonist
- pain
- anticipators
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Anesthesiology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Abstract
Η εφεύρεση αφορά τη χρησιμοποίηση ενώσεων, οι οποίες παρουσιάζουν μία χημική συγγένεια προς τον υποδοχέα μ-οπιοειδών από τουλάχιστον 100 nΜ (ανθρώπινη τιμή Κi) και μία χημική συγγένεια προς τον ORL1 -υποδοχέα, όπου η αναλογία μεταξύ χημικών συγγενειών ORL1/μ, προσδιορισμένη σαν 1/[Ki(ORL1)/Κi(μ)], βρίσκεται από 0,1 έως 30, για την παρασκευή ενός φαρμάκου για τη θεραπεία πόνου.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102006046745A DE102006046745A1 (de) | 2006-09-29 | 2006-09-29 | Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz |
EP07818462A EP2081571B1 (de) | 2006-09-29 | 2007-09-26 | GEMISCHTE ORL1/µ -AGONISTEN ZUR BEHANDLUNG VON SCHMERZ |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1110879T1 true CY1110879T1 (el) | 2015-06-10 |
Family
ID=38982475
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20101100993T CY1110879T1 (el) | 2006-09-29 | 2010-11-03 | ΧΑΡΑΚΤΗΡΙΣΜΟΣ: ΑΝΑΜΙΚΤΟΙ ORL1/μ-ΑΓΩΝΙΣΤΕΣ ΓΙΑ ΤΗ ΘΕΡΑΠΕΙΑ ΠΟΝΟΥ |
CY20121100252T CY1112471T1 (el) | 2006-09-29 | 2012-03-12 | Αναμικτοι orl1/μ-αγωνιστες για τη θεραπεια πονου |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20121100252T CY1112471T1 (el) | 2006-09-29 | 2012-03-12 | Αναμικτοι orl1/μ-αγωνιστες για τη θεραπεια πονου |
Country Status (13)
Country | Link |
---|---|
US (3) | US20080125475A1 (el) |
EP (2) | EP2206498B9 (el) |
JP (2) | JP5203373B2 (el) |
AT (2) | ATE542532T1 (el) |
CA (1) | CA2664702C (el) |
CY (2) | CY1110879T1 (el) |
DE (2) | DE102006046745A1 (el) |
DK (2) | DK2206498T3 (el) |
ES (2) | ES2351528T3 (el) |
PL (2) | PL2081571T3 (el) |
PT (2) | PT2206498E (el) |
SI (2) | SI2206498T1 (el) |
WO (1) | WO2008040481A1 (el) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10252667A1 (de) | 2002-11-11 | 2004-05-27 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
DE102006046745A1 (de) * | 2006-09-29 | 2008-04-03 | Grünenthal GmbH | Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz |
DE102007009235A1 (de) * | 2007-02-22 | 2008-09-18 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
DE102007009319A1 (de) * | 2007-02-22 | 2008-08-28 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
ES2523580T3 (es) | 2008-01-11 | 2014-11-27 | Albany Molecular Research, Inc. | Piridoindoles substituidos con (1-Azinona) |
ES2621407T3 (es) | 2008-03-27 | 2017-07-04 | Grünenthal GmbH | Ciclohexildiaminas sustituidas |
AU2009228643B2 (en) | 2008-03-27 | 2013-07-11 | Grunenthal Gmbh | Spiro(5.5)undecane derivatives |
CA2719742C (en) | 2008-03-27 | 2016-11-08 | Gruenenthal Gmbh | Substituted spirocyclic cyclohexane derivatives |
PE20121314A1 (es) | 2008-03-27 | 2012-10-07 | Gruenenthal Chemie | Derivados de 4-aminociclohexano sustituido |
PT2271613E (pt) | 2008-03-27 | 2014-07-16 | Gruenenthal Gmbh | Hidroximetilciclo-hexilamina |
US8629158B2 (en) * | 2009-07-01 | 2014-01-14 | Albany Molecular Research, Inc. | Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof |
WO2011003005A1 (en) * | 2009-07-01 | 2011-01-06 | Albany Molecular Research, Inc. | Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine mch-1 antagonists, methods of making, and use thereof |
WO2011003021A1 (en) * | 2009-07-01 | 2011-01-06 | Albany Molecular Research, Inc. | Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof |
WO2011003012A1 (en) * | 2009-07-01 | 2011-01-06 | Albany Molecular Research, Inc. | Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof |
DE102009041581B4 (de) | 2009-09-15 | 2011-09-29 | Airbus Operations Gmbh | Vorrichtung zur Abgrenzung eines Crew-Ruhebereichs und Verfahren zur Inbetriebnahme einer derartigen Vorrichtung |
TWI582092B (zh) * | 2010-07-28 | 2017-05-11 | 歌林達股份有限公司 | 順式-四氫-螺旋(環己烷-1,1’-吡啶[3,4-b]吲哚)-4-胺-衍生物 |
MX345068B (es) * | 2010-08-04 | 2017-01-16 | Gruenenthal Gmbh | Forma de dosificacion farmaceutica que comprende 6'-fluoro-(n-metil- o n,n-dimetil-)-4-fenil-4', 9'-dihidro-3'h-espiro[ciclohexan-1,1'-pirano[3,4,b]indol]-4-amina . |
JP5792299B2 (ja) * | 2010-08-04 | 2015-10-07 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 神経因性疼痛の治療のための6’−フルオロ−(N−メチル−又はN,N−ジメチル−)−4−フェニル−4’,9’−ジヒドロ−3’H−スピロ[シクロヘキサン−1,1’−ピラノ[3,4,b]インドール]−4−アミンを含む医薬剤形 |
ES2553742T3 (es) * | 2010-08-04 | 2015-12-11 | Grünenthal GmbH | Forma de dosificación farmacéutica que comprende 6'-fluor-(N-metil- o N,N-dimetil)-4-fenil-4',9'-dihidro-3'H-espiro[ciclohexano-1,1'-pirano[3,4,b]indol]-4-amina |
EP2600846B1 (en) * | 2010-08-04 | 2015-11-25 | Grünenthal GmbH | Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cylohexane-1,1'-pyrano[3,4,b]indol]-4-amine |
WO2012088038A2 (en) | 2010-12-21 | 2012-06-28 | Albany Molecular Research, Inc. | Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof |
US8993765B2 (en) | 2010-12-21 | 2015-03-31 | Albany Molecular Research, Inc. | Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof |
LT2729470T (lt) | 2011-07-08 | 2017-08-25 | Grünenthal GmbH | Kristalinis (1r,4r)-6`-fluor-n,n-dimetil-4-fenil-4`,9`-dihidro-3`h-spiro[cikloheksan-1,1`-pirano[3,4,b]indol]-4-aminas |
US8614245B2 (en) | 2011-07-08 | 2013-12-24 | Gruenenthal Gmbh | Crystalline (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine |
US8779160B2 (en) | 2011-12-12 | 2014-07-15 | Gruenenthal Gmbh | Process for the preparation of (1r,4r)-6′-fluoro-(N,N-dimethyl- and N-methyl)-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine |
CN106432256B (zh) | 2011-12-12 | 2019-08-09 | 格吕伦塔尔有限公司 | 盐酸盐的固体形式 |
TWI567078B (zh) | 2011-12-12 | 2017-01-21 | 歌林達有限公司 | (1r,4r)-6’-氟-(N,N-二甲基)-4-苯基-4’,9’-二氫-3’H-螺-[環己烷-1,1’-吡喃並-[3,4,b]吲哚]-4-胺及硫酸之固體形式 |
US20130211351A1 (en) | 2012-01-31 | 2013-08-15 | Gruenenthal Gmbh | Pharmaceutical patch for transdermal administration of (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4-b]indol]-4-amine |
MX353740B (es) * | 2012-02-03 | 2018-01-26 | Gruenenthal Gmbh | (1r,4r)-6´-fluoro-(n-metil- o n,n-dimetil-)-4-fenil-4´,9´-dihidro- 3´h-espiro-[ciclohexano-1,1´-pirano[3,4,b]indol]-4-amina para el tratamiento de fibromialgia y sindrome de fatiga cronica. |
US9320729B2 (en) | 2012-05-18 | 2016-04-26 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative |
US9345689B2 (en) * | 2012-05-18 | 2016-05-24 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant |
US9855286B2 (en) * | 2012-05-18 | 2018-01-02 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component |
US20130310435A1 (en) | 2012-05-18 | 2013-11-21 | Gruenenthal Gmbh | Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol |
US8912226B2 (en) | 2012-05-18 | 2014-12-16 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r) -6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a NSAR |
US9308196B2 (en) * | 2012-05-18 | 2016-04-12 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam |
US20130310385A1 (en) | 2012-05-18 | 2013-11-21 | Gruenenthal Gmbh | Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants |
US9320725B2 (en) | 2012-05-18 | 2016-04-26 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid |
US9358022B2 (en) | 2012-05-21 | 2016-06-07 | Noha, Llc | Clot removal device and method of using same |
WO2015128088A1 (en) | 2014-02-27 | 2015-09-03 | Grünenthal GmbH | Process for the preparation of 5-fluorotryptophol |
JP6673924B2 (ja) | 2015-01-23 | 2020-03-25 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 肝機能障害および/または腎機能障害を有する対象における疼痛を治療するためのセブラノパドール |
MX2018010367A (es) | 2016-02-29 | 2018-12-10 | Guenenthal Gmbh | Titulacion de cebranopadol. |
WO2024129782A1 (en) | 2022-12-12 | 2024-06-20 | Park Therapeutics, Inc. | Regimens and compositions useful for alleviating pain |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2226058C (en) * | 1997-01-30 | 2008-01-29 | F. Hoffmann-La Roche Ag | 8-substituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives |
US20040038970A1 (en) * | 1998-06-12 | 2004-02-26 | Societe De Conseils De Recherches Etd' Application Scientifiques, S.A.S. A Paris, France Corp. | Beta-carboline compounds |
NZ508765A (en) * | 1998-06-12 | 2003-10-31 | Sod Conseils Rech Applic | Beta-carboline derivatives and pharmaceuticals thereof that selectively bind somatostatin receptor subtypes |
ID29137A (id) * | 1998-07-27 | 2001-08-02 | Schering Corp | Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1 |
ATE289307T1 (de) * | 1998-10-23 | 2005-03-15 | Pfizer | 1,3,8-triazaspiro(4,5) decanon verbindungen als orl1-receptor agonisten |
EP1537110B1 (en) * | 1999-12-06 | 2007-01-17 | Euro-Celtique, S.A. | Triazospiro compounds having nociceptin receptor affinity |
ATE302770T1 (de) * | 1999-12-06 | 2005-09-15 | Euro Celtique Sa | Benzimidazolverbindungen die nociceptinrezeptoraffinität haben |
CA2439859A1 (en) * | 2001-03-02 | 2002-09-12 | Donna-Donigi Gale | N-but-3-enyl norbuprenorphine and its use as analgesic |
MY126268A (en) * | 2001-11-07 | 2006-09-29 | Schering Corp | Heteroaryl derivatives as superior ligands for nociceptin receptor orl-1 |
DE10252667A1 (de) * | 2002-11-11 | 2004-05-27 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
DE10252666A1 (de) * | 2002-11-11 | 2004-08-05 | Grünenthal GmbH | N-Piperidyl-cyclohexan-Derivate |
DE10252665A1 (de) * | 2002-11-11 | 2004-06-03 | Grünenthal GmbH | 4-Aminomethyl-1-aryl-cyclohexylamin-Derivate |
EP1560806B1 (de) * | 2002-11-12 | 2007-01-10 | Grünenthal GmbH | 4-alkyl-/4-alkenyl-/4-alkinylmethyl/-1-arylcyclohexylamin-derivate |
WO2005016913A1 (en) * | 2003-08-19 | 2005-02-24 | Pfizer Japan, Inc. | Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders |
WO2005033112A2 (en) * | 2003-10-02 | 2005-04-14 | Cephalon, Inc. | Substituted indole derivatives |
DE10360793A1 (de) * | 2003-12-23 | 2005-07-28 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
DE10360792A1 (de) * | 2003-12-23 | 2005-07-28 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
JP2005314347A (ja) * | 2004-04-30 | 2005-11-10 | Japan Tobacco Inc | 疼痛抑制剤 |
DE102004023635A1 (de) * | 2004-05-10 | 2006-04-13 | Grünenthal GmbH | Heteroarylsubstituierte Cyclohexyl-1,4-diamin-Derivate |
DE102006046745A1 (de) * | 2006-09-29 | 2008-04-03 | Grünenthal GmbH | Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz |
-
2006
- 2006-09-29 DE DE102006046745A patent/DE102006046745A1/de not_active Withdrawn
-
2007
- 2007-09-26 PT PT10003202T patent/PT2206498E/pt unknown
- 2007-09-26 DK DK10003202.8T patent/DK2206498T3/da active
- 2007-09-26 ES ES07818462T patent/ES2351528T3/es active Active
- 2007-09-26 EP EP10003202A patent/EP2206498B9/de active Active
- 2007-09-26 DK DK07818462.9T patent/DK2081571T3/da active
- 2007-09-26 PL PL07818462T patent/PL2081571T3/pl unknown
- 2007-09-26 DE DE502007004875T patent/DE502007004875D1/de active Active
- 2007-09-26 ES ES10003202T patent/ES2377482T3/es active Active
- 2007-09-26 PT PT07818462T patent/PT2081571E/pt unknown
- 2007-09-26 WO PCT/EP2007/008379 patent/WO2008040481A1/de active Application Filing
- 2007-09-26 AT AT10003202T patent/ATE542532T1/de active
- 2007-09-26 SI SI200730850T patent/SI2206498T1/sl unknown
- 2007-09-26 JP JP2009529599A patent/JP5203373B2/ja not_active Expired - Fee Related
- 2007-09-26 CA CA2664702A patent/CA2664702C/en not_active Expired - Fee Related
- 2007-09-26 PL PL10003202T patent/PL2206498T3/pl unknown
- 2007-09-26 AT AT07818462T patent/ATE478667T1/de active
- 2007-09-26 SI SI200730414T patent/SI2081571T1/sl unknown
- 2007-09-26 EP EP07818462A patent/EP2081571B1/de active Active
- 2007-09-28 US US11/864,080 patent/US20080125475A1/en not_active Abandoned
-
2010
- 2010-09-21 US US12/887,102 patent/US20110015220A1/en not_active Abandoned
- 2010-11-03 CY CY20101100993T patent/CY1110879T1/el unknown
-
2012
- 2012-03-12 CY CY20121100252T patent/CY1112471T1/el unknown
-
2013
- 2013-02-12 JP JP2013024900A patent/JP5698282B2/ja not_active Expired - Fee Related
-
2015
- 2015-06-05 US US14/732,451 patent/US20150342929A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ES2377482T3 (es) | 2012-03-28 |
PT2206498E (pt) | 2012-02-15 |
DK2081571T3 (da) | 2010-11-08 |
EP2081571B1 (de) | 2010-08-25 |
ATE542532T1 (de) | 2012-02-15 |
PL2206498T3 (pl) | 2012-04-30 |
DE502007004875D1 (de) | 2010-10-07 |
US20150342929A1 (en) | 2015-12-03 |
CA2664702C (en) | 2016-08-09 |
DK2206498T3 (da) | 2012-03-19 |
DE102006046745A1 (de) | 2008-04-03 |
ATE478667T1 (de) | 2010-09-15 |
SI2081571T1 (sl) | 2010-12-31 |
SI2206498T1 (sl) | 2012-03-30 |
JP2013116907A (ja) | 2013-06-13 |
ES2351528T3 (es) | 2011-02-07 |
US20080125475A1 (en) | 2008-05-29 |
JP5203373B2 (ja) | 2013-06-05 |
US20110015220A1 (en) | 2011-01-20 |
CA2664702A1 (en) | 2008-04-10 |
EP2206498B9 (de) | 2012-04-18 |
EP2206498A1 (de) | 2010-07-14 |
EP2206498B1 (de) | 2012-01-25 |
PT2081571E (pt) | 2010-11-29 |
WO2008040481A1 (de) | 2008-04-10 |
PL2081571T3 (pl) | 2011-02-28 |
JP5698282B2 (ja) | 2015-04-08 |
EP2081571A1 (de) | 2009-07-29 |
JP2010504926A (ja) | 2010-02-18 |
CY1112471T1 (el) | 2015-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1112471T1 (el) | Αναμικτοι orl1/μ-αγωνιστες για τη θεραπεια πονου | |
Vallejo et al. | Pharmacology of opioids in the treatment of chronic pain syndromes | |
Pascoe | Opioid analgesics | |
Lalley | μ-Opioid receptor agonist effects on medullary respiratory neurons in the cat: evidence for involvement in certain types of ventilatory disturbances | |
White et al. | Pharmacological properties of ketamine | |
Robertson | Managing pain in feline patients | |
KR101195819B1 (ko) | 하지 불안 증후군 및 중독 질환을 치료하는데 유용한α-아미노아미드 유도체 | |
Lê et al. | Operant self-administration of alcohol and nicotine in a preclinical model of co-abuse | |
JP2010513569A (ja) | アルコール摂取に対するトピラメートおよびオンダンセトロンの併用効果 | |
Emery et al. | Drug-specific differences in the ability of opioids to manage burn pain | |
JP2015509075A (ja) | ノルイボガインの硫酸エステル | |
WO2008025790A3 (en) | Use of opioid formulations in needle-less drug delivery devices | |
May et al. | Morphine has latent deleterious effects on the ventilatory responses to a hypoxic challenge | |
Seckler et al. | Nitrosyl factors play a vital role in the ventilatory depressant effects of fentanyl in unanesthetized rats | |
Taffe et al. | Effects of α-pyrrolidino-phenone cathinone stimulants on locomotor behavior in female rats | |
NZ590981A (en) | Transdermal therapeutic system (TTS) for administration with a wafer | |
Getsy et al. | L-NAC reverses of the adverse effects of fentanyl infusion on ventilation and blood-gas chemistry | |
Gregoretti et al. | Clonidine in perioperative medicine and intensive care unit: more than an anti-hypertensive drug | |
Sorge et al. | The effects of chronic buprenorphine on intake of heroin and cocaine in rats and its effects on nucleus accumbens dopamine levels during self-administration | |
WO2007035879A3 (en) | Combination s-nitrosothiol-based pharmaceutical products for restoring normal breathing rhythm | |
Sanghvi et al. | Comparative study of bupivacaine alone and bupivacaine along with buprenorphine in axillary brachial plexus block: a prospective, randomized, single blind study | |
Lehmann | Opioids: overview on action, interaction and toxicity | |
Park et al. | The influence of age and gender on remifentanil EC50 for preventing rocuronium induced withdrawal movements | |
Ko et al. | Pleiotropic effects of kappa opioid receptor-related ligands in non-human primates | |
Gerak et al. | OREX-1038: a potential new treatment for pain with low abuse liability and limited adverse effects |